A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Abroad (travel likely)RecruitingPHASE1

Conditions

Hepatic Impairment (HI)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States
Texas Liver Institute ( Site 0002), San Antonio, Texas, United States
Study coordinator · 210-253-3426

Study leads

Medical Director
Study Director
Merck Sharp & Dohme LLC

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function

Healthy Adult Participants · Hepatic Impairment (HI)

Abroad (travel likely)RecruitingPHASE1

Bengbu, China

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Hepatic Impairment (HI)

Abroad (travel likely)RecruitingPHASE1

Miami, United States · Orlando, United States

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Hepatic Impairment · Moderate Hepatic Impairment

Abroad (travel likely)RecruitingPHASE1

Orlando, United States · San Antonio, United States